We are live on
!
Find out more
CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.67B
1-Year Est. Return
89%
This Fund
S&P 500
This Quarter
Est. Return
+46.89%
1 Year Est. Return
+89%
3 Year Est. Return
+264.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.67B
AUM Growth
+$351M
(+27%)
Cap. Flow
+$70.1M
Cap. Flow
% of AUM
4.19%
Top 10 Holdings %
Top 10 Hldgs %
34.79%
Holding
547
New
45
Increased
181
Reduced
257
Closed
36
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$11.8M |
| 2 |
NVIDIA
NVDA
|
+$8.71M |
| 3 |
Apple
AAPL
|
+$8.26M |
| 4 |
SNDK
Sandisk
SNDK
|
+$7.29M |
| 5 |
Marvell Technology
MRVL
|
+$5.44M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Gold Trust
IAU
|
+$8.15M |
| 2 |
SPDR Gold Trust
GLD
|
+$7.23M |
| 3 |
SPDR Gold MiniShares Trust
GLDM
|
+$6.88M |
| 4 |
AstraZeneca
AZN
|
+$5.05M |
| 5 |
British American Tobacco
BTI
|
+$2.74M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 47.74% |
| 2 | Healthcare | 19.17% |
| 3 | Communication Services | 9.91% |
| 4 | Consumer Discretionary | 7.67% |
| 5 | Consumer Staples | 3.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
476
InflaRx
IFRX
$252M
| $35.8K | ﹤0.01% |
+16,000
| New | +$30.1K |
|
|
NBP
477
NovaBridge Biosciences American Depositary Shares
NBP
$209M
| $34.8K | ﹤0.01% |
17,864
-2,055
| -10% | -$4.19K |
|
478
Coherus Oncology
CHRS
$225M
| $34.4K | ﹤0.01% |
24,549
-1,976
| -7% | -$3.23K |
|
479
Keros Therapeutics
KROS
$205M
| $33.7K | ﹤0.01% |
3,150
-2,256
| -42% | -$25.1K |
|
480
Voyager Therapeutics
VYGR
$186M
| $33.7K | ﹤0.01% |
9,616
-842
| -8% | -$3.19K |
|
481
Codexis
CDXS
$135M
| $32.7K | ﹤0.01% |
14,466
-1,563
| -10% | -$3.89K |
|
|
BCYC
482
Bicycle Therapeutics
BCYC
$279M
| $31.5K | ﹤0.01% |
7,420
-802
| -10% | -$3.68K |
|
483
Lifecore Biomedical
LFCR
$162M
| $31.3K | ﹤0.01% |
5,970
-679
| -10% | -$3.42K |
|
484
Arcturus Therapeutics
ARCT
$164M
| $30.4K | ﹤0.01% |
4,524
-518
| -10% | -$4.08K |
|
485
Pyxis Oncology
PYXS
$182M
| $30.4K | ﹤0.01% |
10,083
-966
| -9% | -$1.85K |
|
|
LENZ
486
LENZ Therapeutics
LENZ
$180M
| $28.3K | ﹤0.01% |
4,990
-563
| -10% | -$4.54K |
|
487
Quantum-Si Incorporated
QSI
$171M
| $27.9K | ﹤0.01% |
31,484
-3,218
| -9% | -$3.06K |
|
488
Caribou Biosciences
CRBU
$160M
| $27.8K | ﹤0.01% |
15,785
-802
| -5% | -$1.58K |
|
489
Humacyte
HUMA
$180M
| $27.6K | ﹤0.01% |
35,334
+1,085
| +3% | +$1K |
|
490
ALX Oncology
ALXO
$277M
| $25.9K | ﹤0.01% |
+12,500
| New | +$22.4K |
|
491
Tenaya Therapeutics
TNYA
$167M
| $25.5K | ﹤0.01% |
34,535
-3,931
| -10% | -$2.98K |
|
|
MENS
492
Jyong Biotech
MENS
$184M
| $25K | ﹤0.01% |
12,100
-1,073
| -8% | -$2.28K |
|
493
ProQR Therapeutics
PRQR
$250M
| $23.3K | ﹤0.01% |
12,500
-7,500
| -38% | -$12.3K |
|
494
Tiziana Life Sciences
TLSA
$118M
| $23K | ﹤0.01% |
+18,000
| New | +$23.4K |
|
|
ADIL
495
Adial Pharmaceuticals
ADIL
$6.26M
| $20.5K | ﹤0.01% |
+8,000
| New | +$15.8K |
|
|
AARD
496
Aardvark Therapeutics
AARD
$140M
| $20K | ﹤0.01% |
3,472
-392
| -10% | -$1.83K |
|
497
PepGen
PEPG
$134M
| $19.8K | ﹤0.01% |
11,008
-1,192
| -10% | -$1.94K |
|
498
DiaMedica Therapeutics
DMAC
$366M
| $17.6K | ﹤0.01% |
2,500
-2,500
| -50% | -$15.4K |
|
499
Black Diamond Therapeutics
BDTX
$101M
| $16.9K | ﹤0.01% |
9,120
-991
| -10% | -$2.42K |
|
|
ARTV
500
Artiva Biotherapeutics
ARTV
$505M
| $15.5K | ﹤0.01% |
+1,600
| New | +$14.6K |
|
Similar funds
HA
TFS
GC
PA
JPM
NRI
CPO
LCI
China Universal Asset Management Company's Q2 2026 Portfolio in Review
As of Q2 2026, China Universal Asset Management Company held 547 positions worth $1.67B, up 27% from $1.32B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
China Universal Asset Management Company deployed $70.1M of net new capital in Q2 2026, opening 45 new positions and adding to 181 existing holdings. Its largest new stake was Onto Innovation: 10,200 shares worth $3.86M.
By sector, the portfolio is most concentrated in Technology at 48% of assets, up from 35% a quarter earlier, followed by Healthcare and Communication Services.
On the sell side, the largest reduction was iShares Gold Trust, an estimated $8.15M trimmed.
- China Universal Asset Management Company's largest Q2 2026 buy was Onto Innovation: 10,200 shares worth $3.86M.
- China Universal Asset Management Company added most to Amazon in Q2 2026, an estimated $11.8M increase.
- China Universal Asset Management Company's biggest Q2 2026 reduction was iShares Gold Trust, cutting an estimated $8.15M.
- China Universal Asset Management Company fully exited AstraZeneca in Q2 2026, selling an estimated $5.05M.
- China Universal Asset Management Company's ten largest holdings make up 35% of its $1.67B portfolio in Q2 2026.
- China Universal Asset Management Company opened 45 new positions and closed 36 in Q2 2026.
- China Universal Asset Management Company's portfolio value rose 27% quarter-over-quarter to $1.67B.
Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.